Pharmabiz3 日
UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis ...
UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...
Healio4 日
Rezpegaldesleukin gets FDA fast track designation for atopic dermatitis
The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...
openaccessgovernment3 日
Nenolizumab has recently been approved for two chronic skin conditions
A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two skin conditions ...
Dupixent® (Dupilumab) Sbla Accepted For FDA Priority Review For The Targeted Treatment Of ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 </stron ...
Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) sBLA Accepted for FDA Priority Review ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...
Healio22 時間
Connection between skin disease, heart health ushers in ‘holistic’ era of dermatology
In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...